Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.1 (
phosphodiesterase
)
18,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Maternal hyperglycemia during pregnancy is associated with excess fetal growth and adverse perinatal and developmental outcomes. Placental epigenetic maladaptation may underlie these associations. We performed an epigenome-wide association study (>850,000 CpG sites) of term placentas and prenatal maternal glycemic response 2-h post oral glucose challenge at 24-30 weeks of gestation among 448 mother-infant pairs. Maternal 2-h glycemia postload was strongly associated with lower DNA methylation of four CpG sites (false discovery rate [FDR]
q
<0.05) within the
phosphodiesterase
4B gene (
PDE4B
). Additionally, three other individual CpG sites were differentially methylated relative to maternal glucose response within the
TNFRSF1B
,
LDLR
, and
BLM
genes (FDR
q
<0.05). DNA methylation correlated with expression of its respective genes in placental tissue at three out of four independent identified loci:
PDE4B
(
r
= 0.31,
P
< 0.01),
TNFRSF1B
(
r
= -0.24,
P
= 0.013), and
LDLR
(
r
= 0.32,
P
< 0.001). In an independent replication cohort (
N
= 65-108 samples), results were consistent in direction but not significantly replicated among tested CpG sites in
PDE4B
and
TNFRSF1B
Our study provides evidence that maternal glycemic response during pregnancy is associated with placental DNA methylation of key inflammatory genes whose expression levels are partially under epigenetic control.
...
PMID:Placental DNA Methylation Adaptation to Maternal Glycemic Response in Pregnancy. 2975 24